EMA's Executive Director, Guido Rasi received the 2014 European Rare Disease Leadership Award 2014.
The European Medicines Agency's Executive Director, Guido Rasi, together with Paola Testori Coggi from the European Commission and Luca Pani from AIFA, have received the 2014 European Rare Disease Leadership Award 2014.
The award has been given by EURORDIS, a non-governmental patient-driven alliance of patient organizations representing 614 rare disease patient groups in 58 countries.
Today, 28 February 2014, is Rare Disease Day, and EURORDIS is planning a series of activities and events, including a television interview in Kenya, a Fun Play Day in Lebanon, an informational awareness-raising campaign in Paraguay, a march in Austria, an auction in Canada, a photo exhibit in China, and a seminar in India. It says thousands of participants from over 80 countries will be involved in the event.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.